Biotinylated Human Siglec-2 / CD22 Protein, Fc, Avitag™ (MALS verified)

B-cell receptor CD22 is also known as Sialic acid-binding Ig-like lectin 2 (Siglec-2), B-lymphocyte cell adhesion molecule (BL-CAM), T-cell surface antigen Leu-14, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. CD22 mediates B-cell B-cell interactions, and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2 / CD22 binds sialylated glycoproteins, one of which is CD45. Siglec2 / CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

Product Specifications

Background

Specifications

This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 103.91 kDa. The protein migrates as 115-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

P20273-1

Expression Region

Asp 20 - Arg 687

Host

HEK293

Target

Siglec-2

Conjugation

Biotin-labeled

Tag

C-Fc & C-Avi

Source

Human

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

0.2 EU per μg

Purity

95%

Bioactivity

Immobilized Monoclonal Anti-Human CD22 Antibody, Human IgG1 at 0.5 μg/mL (100 μL/well) can bind Biotinylated Human Siglec-2, Fc,Avitag (Cat. No. SI2-H82F8) with a linear range of 1-16 ng/mL (QC tested).